Avalyn Pharma Inc. (AVLN) Income Statement
AVLN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAVLN revenue and net income
AVLN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AVLN quarterly EPS vs estimates
Avalyn Pharma beat the analyst EPS estimate in 1 of the last 2 quarters. Next report: November 11, 2026 (estimate $-0.64).
AVLN income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $76.6M | $45.8M |
| Sales, general & admin | $14.7M | $11.4M |
| Total operating expenses | $91.3M | $57.1M |
| Operating income | −$91.3M | −$57.1M |
| Interest income | $6.2M | $7.4M |
| Income before taxes | −$85.2M | −$49.7M |
| Net income | −$85.2M | −$49.7M |
| EBITDA | −$91.2M | −$57.1M |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $110,000 | — | — | — |
| Gross profit | −$110,000 | — | — | — |
| Research & development | $24.7M | $22.9M | $17.9M | $15.3M |
| Sales, general & admin | $6.6M | $5.0M | $3.9M | $3.4M |
| Total operating expenses | $31.2M | $27.9M | $21.8M | $18.7M |
| Operating income | −$31.3M | −$27.9M | −$21.8M | −$18.7M |
| Interest income | $2.7M | $1.1M | $1.6M | $1.2M |
| Interest expense | $272,000 | $98,000 | $0 | $0 |
| Income before taxes | −$28.9M | −$26.9M | −$20.2M | −$17.5M |
| Net income | −$28.9M | −$26.9M | −$20.2M | −$17.5M |
| EBITDA | −$31.2M | −$26.7M | −$20.2M | −$17.5M |
| EPS (diluted) | −$0.98 | −$21.83 | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AVLN's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AVLN financial results
Avalyn Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $85.2 million.
See the AVLN stock overview for the latest quote and news, or the AVLN chart for price history and technical indicators.
AVLN income statement FAQ
Does Avalyn Pharma have revenue?
Avalyn Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Avalyn Pharma profitable?
No. Avalyn Pharma reported a net loss of $85.2 million in fiscal 2025.
How much does Avalyn Pharma spend on research and development?
Avalyn Pharma spent $76.6 million on research and development in fiscal 2025.
When will Avalyn Pharma report its next earnings?
Avalyn Pharma is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Avalyn Pharma's fiscal year end?
Avalyn Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.